

Resource Summary Report

Generated by ASWG on Aug 7, 2026

BD Biosciences: FACSCalibur Flow Cytometry System

RRID:SCR_000401

Type: Tool

Proper Citation

BD Biosciences: FACSCalibur Flow Cytometry System (RRID:SCR_000401)

Resource Information

URL:

https://www.bdbiosciences.com/documents/FACSCalibur_FlowCytometry_TechSpec.pdf

Proper Citation: BD Biosciences: FACSCalibur Flow Cytometry System (RRID:SCR_000401)

Description: Automated benchtop flow cytometry system. It allows measuring four fluorochrome-conjugates, forward and side scatter., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Abbreviations: BD FACSCalibur system

Synonyms: FACSCalibur flow cytometer

Resource Type: instrument resource

Keywords: flow cytometry, hardware, instrument, equipment

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Specification URL:

https://drive.google.com/file/d/1v6yeGI7IxHS0_Ezn35dZ9qzu27jIBh52/view?usp=drivesdk

Resource Name: BD Biosciences: FACSCalibur Flow Cytometry System

Resource ID: SCR_000401

Alternate IDs: SciRes_000153

Alternate URLs: https://www.bdbiosciences.com/content/dam/bdb/marketing-documents/BD_FACSCalibur_instructions.pdf

License: Commercial license

Record Creation Time: 20220129T080201+0000

Record Last Update: 20260801T190116+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: FACSCalibur Flow Cytometry System.

No alerts have been found for BD Biosciences: FACSCalibur Flow Cytometry System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 411 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Jana S, et al. (2026) Collagen-Bearing Exosomes from Breast Cancer-Associated Fibroblasts Promote T-cell Dysfunction. Cancer research communications, 6(3), 630.

Liu CT, et al. (2026) Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. Cancer research communications, 6(3), 616.

Yee SM, et al. (2026) A distinct TCR+CD19+ population in the peritoneal cavity: B1a cells as precursors of extrathymic T cells. iScience, 29(4), 115505.

Ali MA, et al. (2026) CD47 Promotes, While Exposure to Apoptotic Cells Destroys the Fusion Program of Differentiating Myoblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(4), e71578.

Tirado-Herranz A, et al. (2026) The autoimmune regulator (AIRE) is a target of the E3-Ubiquitin ligase Seven-in-absentia homolog 1 (SIAH1). Apoptosis : an international journal on programmed cell death, 31(8).

Cheema PS, et al. (2026) Identification and validation of novel small molecule inhibitors targeting FoxM1-DNA binding domain with anti-cancer potential. Biochimica et biophysica acta. Molecular cell research, 1873(7), 120193.

Greenman M, et al. (2025) Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer research communications, 5(5), 774.

Santin NG, et al. (2025) Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. *Cancer research communications*, 5(9), 1611.

Cai MY, et al. (2025) Dual regulation of FZD1/7 by IGF2BP3 enhances stem-like properties and carboplatin resistance in triple-negative breast cancer. *Cancer letters*, 632, 217944.

Zubiaur M, et al. (2025) CD38 deficiency leads to a defective short-lived transcriptomic response to chronic graft-versus-host disease induction, involving purinergic signaling-related genes and distinct transcriptomic signatures associated with lupus. *Frontiers in immunology*, 16, 1441981.

Pournajaf S, et al. (2025) Fingolimod Inhibits C6 Rat Glioma Proliferation and Migration, Induces Sub-G1 Cell Cycle Arrest, Mitochondrial and Extrinsic Apoptosis In Vitro and Reduces Tumour Growth In Vivo. *Clinical and experimental pharmacology & physiology*, 52(1), e70012.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Vax E, et al. (2025) A novel Frizzled 7 antibody disrupts the Wnt pathway and inhibits Wilms tumor growth. *Frontiers in bioengineering and biotechnology*, 13, 1641137.

Kawahara N, et al. (2025) Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1 β positive clear cell carcinoma. *Cell death & disease*, 16(1), 879.

Alfaro E, et al. (2024) Endothelial dysfunction and persistent inflammation in severe post-COVID-19 patients: implications for gas exchange. *BMC medicine*, 22(1), 242.

Afsordeh N, et al. (2024) Eslicarbazepine induces apoptosis and cell cycle arrest in C6 glioma cells in vitro and suppresses tumor growth in an intracranial rat model. *BMC cancer*, 24(1), 1099.

Fukushima H, et al. (2024) Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells. *EBioMedicine*, 102, 105050.

Bayat H, et al. (2024) CRISPR/Cas9-mediated deletion of a GA-repeat in human GPM6B leads to disruption of neural cell differentiation from NT2 cells. *Scientific reports*, 14(1), 2136.

Regunath K, et al. (2024) Systematic Characterization of p53-Regulated Long Noncoding RNAs across Human Cancers Reveals Remarkable Heterogeneity among Different Tumor Types. *Molecular cancer research : MCR*, 22(6), 555.

Klement JD, et al. (2023) Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. *Cancer cell*, 41(3), 620.